THEY SAID IT! Lawmakers Vow Action To Lower Insulin Prices & Criticize Pharma For Price-Gouging, Blame Game

04-11-2019 Press Release

Today, the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations held a hearing with representatives of drug manufacturers and pharmacy benefit managers (PBMs) to discuss the sky-rocketing cost of insulin.  Representatives lamented how the high price has caused some of their constituents to resort to drastic measures.  Members of the committee […]

Big Pharma Needs To Be Held Accountable For Lead Role In Rising Insulin Prices

04-10-2019 Press Release

On Wednesday, executives from the three biggest makers of insulin, Novo Nordisk, Eli Lilly and Sanofi, will testify before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations on a hearing about the rising cost of insulin.  These companies say that they’re for affordability and access for patients, but their track […]

CSRxP Applauds Ways & Means Lawmakers For Advancing Prescription Drug STAR Act

04-9-2019 Press Release

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today after the U.S. House Committee on Ways and Means advanced the Prescription Drug STAR Act at a legislative markup on Tuesday. “We applaud members of the Ways and Means Committee for advancing this important measure to help shine light on Big […]

CSRxP: PBMs Cut Through The Big Pharma Blame Game On Capitol Hill

04-9-2019 Press Release

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Tuesday following testimony from five executives representing pharmacy benefit managers (PBMs) before the U.S. Senate Committee on Finance on the issue of drug pricing. “Today’s testimony demonstrated Big Pharma’s blame game targeting PBMs is a mile wide and an inch deep,” said […]

CSRxP Encourages Ways & Means Lawmakers To Advance Prescription Drug STAR Act

04-8-2019 Press Release

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement ahead of a bill markup in the U.S. House Committee on Ways & Means on the Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act (H.R. 2113): “The Prescription Drug STAR Act will help shine light on Big Pharma’s price-gouging and […]

“DOSE OF REALITY” Calling Big Pharma’s Bluff On PBMs: Part IV

04-8-2019 Press Release

Big Pharma has tried to evade culpability for the crisis of rising prescription drug prices by pointing a finger at pharmacy benefit managers (PBMs).  As the U.S. Senate Committee on Finance prepares to hear from the executives of five PBMs on April 9, it’s time to debunk Big Pharma’s bluffs.  PBMs serve an essential role […]

CSRxP: New Study Underscores Big Pharma The Only Rebate Rule Winner

04-8-2019 Press Release

Avalere Health Finds Proposed Rule Could Hike Premiums 40 Percent, Cost Taxpayers Over $400 Billion Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Monday reacting to a new study, conducted by Avalere Health, analyzing three scenarios projecting the impact of the Rebate Rule proposed by the U.S. Department of Health […]

“DOSE OF REALITY” Calling Big Pharma’s Bluff On PBMs: Part III

04-7-2019 Press Release

Big Pharma has tried to evade culpability for the crisis of rising prescription drug prices by pointing a finger at pharmacy benefit managers (PBMs).  As the U.S. Senate Committee on Finance prepares to hear from the executives of five PBMs on April 9, it’s time to debunk Big Pharma’s bluffs.  PBMs serve an essential role […]

Second Opinion: Rebate Rule Would be Revolutionary … For Big Pharma

04-5-2019 Press Release

Nothing in Proposed Rule Guarantees Prices Will Come Down by Full Amount of Rebates On Thursday, U.S. Department of Health and Human Services (HHS) Secretary Alex Azar testified before the U.S. Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies on HHS’ FY2020 budget request.  When asked by Senator […]

“DOSE OF REALITY” Calling Big Pharma’s Bluff On PBMs: Part II

04-5-2019 Press Release

Big Pharma has tried to evade culpability for the crisis of rising prescription drug prices by pointing a finger at pharmacy benefit managers (PBMs).  As the U.S. Senate Committee on Finance prepares to hear from the executives of five PBMs on April 9, it’s time to debunk Big Pharma’s bluffs.  PBMs serve an essential role […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.